Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis
| Condition | Cirrhosis, Hepatocellular Carcinoma |
|---|---|
| Phase | Phase 2 |
| Sponsor | National Cancer Institute (NCI) |
| Status | Active, not recruiting |
| Enrollment | 52 participants |
| Interventions | Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Placebo Administration, Questionnaire Administration |
| Start date | Jun 21, 2017 |
| Completion date | May 3, 2023 |
| Results posted | Apr 15, 2025 |
Summary
This phase II trial studies how well simvastatin works in preventing liver cancer in patients with liver cirrhosis. Simvastatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Change in Serum AFP-L3%
| Group I (Simvastatin) | 0.24 ± 1.00 percent |
|---|---|
| Group II (Placebo) | -0.04 ± 0.11 percent |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Treme — MedImmune LLC
- Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Live — National Cancer Institute (NCI)
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma — CStone Pharmaceuticals
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver C — Edward Kim
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hep — AstraZeneca
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Di — National Cancer Institute (NCI)